Cell and Gene Therapy Investment Tracker: The Latest Deals in 2024

SHARE NOW
Welcome to Phacilitate’s investment tracker where we’ll be looking at the latest deals in the cell and gene therapy industry. We’ll update the cell and gene investment tracker deals weekly.
After a few difficult years, biotech investment is finally on the uptick again. The deals below are organized chronologically.
Poseida Therapeutics (Acquisition by Roche)
Date Announced: November 26
Acquisition Amount: Up to $1.5 billion
Therapeutic Focus: Allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases
Acquisition Focus: To establish a new core capability for Roche in allogeneic cell therapy, with lead opportunities focused on CAR-T programs covered by the existing strategic collaboration between the two companies in hematologic malignancies
For more information, read the press release.
Lineage Cell Therapeutics
Date Announced: November 21
Funding Amount: $66 million
Funding Round: Registered Direct Offering
Investors: Institutional investors and Broadwood Partners
Therapeutic Focus: Allogeneic cell therapies for unmet medical needs
For more information, read the press release.
Valora Therapeutics
Date Announced: November 20
Funding Amount: $30 million
Funding Round: Seed funding
Investors: Avalon BioVentures, Bregua Corporation, and TigerGene with additional participation from Alexandria Venture Investments and Correlation Ventures
Therapeutic Focus: Immunotherapy
For more information, read the press release.
Cytomos
Date Announced: November 19
Funding Amount: £ 5 million
Investors: Led by existing investors Archangels with participation from Old College Capital, Scottish Enterprise and British Business Bank.
Therapeutic Focus: Real-time-single-cell analytics
For more information, read the press release.
ReCode Therapeutics
Date Announced: November 18
Funding Amount: Up to $15 million
Investors: Cystic Fibrosis Foundation (CF Foundation)
Therapeutic Focus: mRNA and gene correction therapeutics
For more information, read the press release.
Vittoria Biotherapeutics
Date Announced: November 12
Funding Amount: $25 million
Funding Round: Private financing
Investors: Led by Valley Forge Investment Corporation, with new investments from the Global BioAccess Fund and Hatch Biofund, alongside ongoing support from existing investors Agent Capital, Tellus BioVentures, NYBC Ventures, and the University of Pennsylvania.
Therapeutic Focus: The funds will primarily support the company’s Phase 1 clinical trial of its lead oncology candidate, VIPER-101, an autologous, dual-population T cell therapy, as a potential treatment of T-cell Lymphoma.
For more information, read the press release.
Neurogene
Date Announced: November 4
Funding Amount: $200 million
Funding Round: A securities purchase agreement for a private investment in public equity (“PIPE”) financing
Investors: RTW Investments, Casdin Capital, EcoR1 Capital, Redmile Group, Great Point Partners, LLC, Commodore Capital and Samsara BioCapital.
Therapeutic Focus: Developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders.
For more information, read the press release
March Biosciences
Date Announced: October 23
Funding Amount:$28.4 million
Funding Round: Series A
Investors: Mission BioCapital and 4BIO Capital led the financing
Therapeutic Focus: The company’s autologous CAR-T therapy, MB-105, has been developed for the treatment of relapsed and refractory CD5 positive T-cell lymphoma.
For more information, read the press release.
Ikarovec
Date Announced: October 23
Funding Amount: A seed fund extension of £5 million, bringing the total to £8 million
Investors: The financing was led by existing investors LifeArc Ventures and Parkwalk Advisors, with UKI2S (managed by Future Planet Capital) also participating in the round.
Therapeutic Focus:The company is developing novel bicistronic gene therapies for major chronic eye disease.
For more information, read the press release.
Be Biopharma
Date Announced: October 22
Funding Amount: $82 million
Investors: Venture capital firms and pharmaceutical companies, including ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers Squibb, and Takeda Ventures.
Therapeutic Focus: The discovery and development of engineered B Cell Medicines
For more information, read the press release.
AvenCell Therapeutics
Date Announced: October 22
Funding Amount: $112 million
Funding Round: Series B
Investors: The financing was led by global life sciences investor Novo Holdings.
Therapeutic Focus: AvenCell Therapeutics is focused on advancing both autologous and allogeneic switchable CAR-T cell therapies.
For more information, read the press release.
Tolerance Bio
Date Announced: October 15
Funding Amount: $17.2 million
Funding Round: Seed funding
Investors: Investment led by Columbus Venture Partners, with participation from Criteria Bio Ventures, Sessa Capital, BioAdvance, Ben Franklin Technology Partners and individual biotechnology investors.
Therapeutic Focus: Tolerance Bio is developing thymus preservation, regeneration, and manipulation platforms to prevent and treat immune diseases.
For more information, read the press release.
Purespring Therapeutics
Date Announced: October 9
Funding Amount: £80 million/$105 million
Funding Round: Series B financing
Investors: Led by Sofinnova Partners in collaboration with Gilde Healthcare, Forbion, British Patient Capital and founding investor Syncona
Therapeutic Focus: gene therapy company focused on transforming the treatment of kidney diseases. Proceeds will be used to support Purespring’s pipeline, including the initiation of a Phase I/II clinical trial for IgAN, a common, chronic kidney disease primarily affecting young adults.
For more information, read the press release.
GEMMA Biotherapeutics
Date Announced: October 8
Funding Amount: Up to $100 million
Investors: Oswaldo Cruz Foundation (“Fiocruz”), a public health research institution that is part of the Ministry of Health of Brazil
Additional Information: GEMMA Biotherapeutics is a new therapeutics company founded by gene therapy pioneer Dr. Jim Wilson. The funding will be used to conduct clinical research and manufacturing
For more information, read the press release.
Resolution Therapeutics
Date Announced: October 3
Funding Amount: £63.5 million
Funding Round: Series B
Investors: The financing was led by Syncona.
Therapeutic Focus: Resolution is focused on unlocking the regenerative potential of macrophage therapy for the treatment of inflammatory and fibrotic diseases.
For more information, read the press release.
ArsenalBio
Date Announced: September 2024
Funding Amount: $325 million
Funding Round: Series C
Investors: The funding round included new investors ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures (NVIDIA’s venture capital arm), Luma Group, funds and accounts advised by T. Rowe Price Associates, Inc., and Rock Springs Capital.
Therapeutic Focus: ArsenalBio is focused on engineering advanced CAR T-cell therapies for solid tumors
For more information, read the press release.